Amgen | AMGN - Current Liabilities


Amgen reported $23.23B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Eli Lilly USD 47B 745M Sep/2026
Exelixis USD 411.88M 49.95M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
J&J USD 55.46B 562M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Moderna USD 2.03B 506M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Takeda JPY 2.6T 161B Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026